CNS Pharmaceuticals, Inc.

US$3.92As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CNSPHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (86.23%)
Div yield —
ROE (106.62%)
Biotechnology
Beta (5Y) 1.01
PE TTM —
TSR TTM (49.09%)
Mkt cap US$5.729M
ROIC (67.23%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.85
(1.74%)
(46.48%)
Hold 5|12|11|0|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.06
0.06
0.07
0.07
20.60%
11.65%
3.45%
8.70%
Revenue$M
0.248
0.246
0.240
0.234
5.47%
3.05%
3.32%
(1.94%)
Peers (US$5.729M)
Cap (US$)
PE
6.217M
—
5.771M
—
5.675M
18.97x
Capital
TTM
5Y
10Y
Leveragex
2.421
0.024
0.019
EBIT/Intx
0.631
0.179
0.173
Own earn%
(33.23)
(56.84)
(57.76)
Sh yield%
35.97
39.39
43.24
Owners
Insiders/Inst%
14.70
49.75
Short interest%
3.34
SBC / revenue%
2.84
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
26–34
$1 testx
—
Incr. ROIC%
63